Authored by Marco Carbone, this case follows a 42-year-old female who presents to the clinic after receiving abnormal liver blood test results. The cases focus on assessing the response to first-line therapy, risk progression, and fatigue management.
Register to access
General Information
Title: PBC Clinical insights: evaluating therapeutic response and disease management
Jointly provided by Postgraduate Institute for Medicine and Springer Healthcare IME
This activity is supported by an independent educational grant from Ipsen
Release date: July 30th 2024
Expiration date: July 30th 2025
Estimated time to complete activity: 15 minutes
Target Audience
This activity is primarily aimed at a global audience of hepatologists and gastroenterologists, and is relevant to all members of the multidisciplinary team that manages PBC patients.
Educational Objectives
After completing this activity, the participant should be better able to:
- Assess the response to first-line therapy and the risk for disease progression in patients with PBC
- Effectively manage and monitor symptoms associated with PBC
Faculty
- Marco Carbone
Associate Professor of Hepatology, University of Milano-Bicocca and Honorary Consultant Hepatologist, Niguarda Liver Transplant Centre, Milan
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:
- Marco Carbone
Honoraria or consultation fees: Ipsen, Advanz, Cymabay, Mayoly Spindler, Falk, Echosens, Zydus, Mirun, GSK
The PIM planners and others have nothing to disclose. The Springer Healthcare IME planners and others have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
